PerkinElmer Inc. expanded the company’s presence in cell biology with the $260 million acquisition of Massachusetts-based Nexcelom Bioscience.

Thermo Fisher Scientific Inc. is acquiring contract researcher PPD Inc. for $17.4 billion as the medical device maker adds more muscle to the company’s pharmaceutical services business.

NeonMind Biosciences Inc., a psychedelic drug development company, announced the appointment of accomplished pharmaceutical executive Robert Tessarolo as President and Chief Executive Officer.

Merck KGaA’s drug development program suffered a setback with the company’s most important experimental medicine as the cancer treatment bintrafusp alfa, being jointly developed by GlaxoSmithKline, failed early in a lead trial.

Immunai, a company comprehensively mapping the immune system, announced a collaboration with leading life science technology company 10x Genomics.

Four more companies secured their place on the stock ticker in a record-breaking year before 2020 comes to a close.  

An historic alliance of life sciences and healthcare organizations seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research.

XtalPi Inc., an AI-based pharmaceutical technology company with an AI-powered platform that twins with existing R&D pipelines, raised an additional $318.8 million through a Series C financing round to bring drug development into the future.

TriNet, a leading global health research network optimizing clinical research to bring new therapies to market faster, announced global investment firm The Carlyle Group made a strategic growth investment and will acquire a majority stake in the company.

The U.S. Centers for Disease Control and Prevention (CDC) asked state public health officials to prepare to distribute a potential coronavirus vaccine to high-risk groups as soon as late October, documents published by the agency showed.